• UCLA Health
  • myUCLAhealth
  • School of Medicine
U Magazine

U Magazine

U Magazine
  • Home
  • Current Issue
  • Centennial Campaign for UCLA Issue
  • Browse U Magazine
  • Letters to the Editor
  • Subscribe
  • Contact
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

U Magazine

Browse U Magazine

  1. Home
  2. Browse U Magazine
Share this
The Cutting Edge

Virus-mimicking Drug Helps Immune System Target Cunning Cancer Cells

Virus-mimicking Drug Helps Immune System Target Cunning Cancer Cells

Immunohistochemical staining analysis at baseline (above) and at relapse (below) in a patient with melanoma that developed acquired genetic resistance to anti–PD-1 ICB. Before treatment with immunotherapy, tumor cells (stained brown in panel S100) are invaded by T cells that produce interferon (IFN)-gamma (stained brown in panel CD8) and, in response, express proteins (MHC I, stained brown in panel MHC I) that allow them to be recognized by the immune system as well as other IFN-reactive proteins (PD-L1, stained brown in panel PD-L1). Image: Dr. Jesse Zaretsky

Virus-mimicking Drug Helps Immune System Target Cunning Cancer Cells

A drug that activates the body’s natural defenses by behaving like a virus may also make certain stealthy melanoma tumors visible to the immune system, allowing them to be better targeted by immunotherapy, a UCLA study has found. The findings open up the possibility of using drugs that mimic viruses to overcome immunotherapy resistance in certain tumors and help to create more personalized therapies for people with hard-to-treat cancers.

Interferons are proteins in cells that respond to viral infection by alerting the immune system to marshal its forces, including T cells, to combat viruses. When it comes to tumors, activating interferon signaling helps slow down tumor division and can lead to the release of molecules that recruit more immune cells to fight the tumor. That concept is the basis for adoptive T-cell therapy, a type of immunotherapy that involves extracting T cells from a patient and engineering them in the laboratory to recognize and kill cancer cells.

However, gene mutations that produced defective interferon signaling allowed some tumors to escape that immune system response. The defective signaling interrupts a critical pathway that normally would allow tumors to increase their antigen presentation — “an intricate machinery that makes tumors visible to T cells,” says Anusha Kalbasi, MD ’11, assistant professor of radiation oncology and member of UCLA’s Jonsson Comprehensive Cancer Center.

To overcome defective interferon signaling, the researchers turned to a virus-mimicking drug, called BO-112, that activates virus-sensing pathways in tumors. When the drug was injected directly into the tumor in the laboratory, the team discovered that the activation of virus-sensing pathways increased antigen presentation even when interferon signaling was defective. As a result, these tumors could be recognized and killed by T cells.

The study “gives us important insights into how tumors are recognized by the immune system,” says Antoni Ribas, MD (FEL ’98, ’01), PhD, director of the tumor immunology program at UCLA’s Jonsson Cancer Center. “New strategies to promote antigen presentation to make tumors more visible to the immune system will allow immunotherapy to be effective for even more tumor types.”

— Denise Heady

Uncoupling Interferon Signaling and Antigen Presentation to Overcome Immunotherapy Resistance Due to JAK1 Loss in Melanoma,” Science Translational Medicine, October 14, 2020


Previous
The Impact of Poverty on Childhood Development Noted in Kids as Young as 5
Next
How To Build A Vaccine


YOU ARE VIEWING

Winter 2021

Winter 2021
Printable PDF
IN THIS ISSUE
  • Now Is the Time
  • The Day the Vaccine Arrived
  • The Art of Sport
  • How Babies Rewire Their Brains to See in 3-D
  • A Step Toward Understanding Why COVID-19 Boosts Stroke Risk
  • Study Finds More Americans Involuntarily Detained Due to Mental Illness
  • Study Illuminates Impact of COVID-19 on Pregnant Women
  • Into the Unknown
  • Fine Family Establishes Endowed Chair in UCLA Department of Surgery
  • A Final Hug with “Mi Amor”
  • Reclaiming Her Voice with a Gift of New Lungs
  • The Impact of Poverty on Childhood Development Noted in Kids as Young as 5
  • Virus-mimicking Drug Helps Immune System Target Cunning Cancer Cells
  • How To Build A Vaccine
  • The Reckoning
  • “This Is Our Moment”
  • Awards and Honors
  • In Memoriam
  • UCLA Health Expresses Gratitude for Board of Advisors Leadership
  • Games, Special Guests and Music Highlight UCLA’s Virtual Party on the Pier
  • Family Establishes Endowed Chair to Memorialize their Daughter
  • In the Quiet of the Holiday Season, the City of Angels Burns
  • A Watershed Moment
  • Race, Racism and Patient Care
  • Modified Blood Test Could Help Predict Pregnancy Complications
  • Into the Woods
  • Annual Tour de Pier Stages a Successful Virtual Event
  • Dr. Jessica Rexach Honored with Endowed Chair
  • Gifts
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest

Sign in to myUCLAhealth

Learn more about myUCLAhealth